SCHEMBL1242382

SCHEMBL1242382

NS(=O)(=O)C1CN(C(c2ccc(F)cc2)C(O)(c2cccnc2)c2cccnc2)C1

nearest known ligand 0.52

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KCNA5 P22460 13/20 0.52
KCNH2 Q12809 10/20 0.52
NPSR1 Q6W5P4 2/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
HTT P42858 1/20 0.40
POLB P06746 1/20 0.37
TSHR P16473 1/20 0.36
LMNA P02545 1/20 0.35
SLC1A3 P43003 1/20 0.35
SLC1A2 P43004 1/20 0.35
SLC1A1 P43005 1/20 0.35
CYP19A1 P11511 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1240800 0.89 KCNA5 (0.52) KCNA5KCNH2NPSR1CYP3A4CYP2D6
SCHEMBL1242998 0.87 KCNA5 (0.49) KCNA5KCNH2NPSR1CYP3A4CYP2D6
SCHEMBL1243184 0.85 KCNA5 (0.57) KCNA5KCNH2NPSR1CYP3A4CYP2D6
SCHEMBL1242756 0.84 KCNA5 (0.58) KCNA5KCNH2NPSR1CYP3A4CYP2D6
SCHEMBL1242334 0.82 KCNA5 (0.49) KCNA5KCNH2NPSR1CYP3A4CYP2D6
SCHEMBL1240939 0.82 KCNA5 (0.49) KCNA5KCNH2NPSR1CYP3A4CYP2D6
SCHEMBL9903352 0.82 KCNA5 (0.44) KCNA5KCNH2NPSR1CYP3A4CYP2D6
SCHEMBL1242312 0.81 KCNA5 (0.50) KCNA5KCNH2NPSR1CYP3A4CYP2D6
SCHEMBL1243568 0.81 KCNA5 (0.54) KCNA5KCNH2NPSR1CYP3A4CYP2D6
SCHEMBL1242857 0.81 KCNA5 (0.54) KCNA5KCNH2NPSR1CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1781635-B1 POTASSIUM CHANNEL INHIBITORS MERCK SHARP & DOHME (US) 2012-06-13 EP disclosed
US-7879839-B2 For treatment and prevention of cardiac arrhythmias; (+-)-2-Morpholin-4-yl-2-phenyl-1,1-dipyridin-3-yl-ethanol; (+-)-2-[(2-methoxyethyl)(methyl)amino]-2-phenyl-1,1-dipyridin-3-ylethanol MERCK SHARP & DOHME CORP. (US) 2011-02-01 US disclosed
US-20080090794-A1 Potassium Channel Inhibitors MERCK SHARP & DOHME LLC 2008-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080090794-A1 Potassium Channel Inhibitors KCNJ2, KCNQ2, KCNH2 KCNA5 11/4885KCNH2 3/4885NPSR1 2052/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.